Evaluation of the therapeutic potential of Garcinia cambogia alone or in combination with Silodosin in the management of LUTS/BPH: A prospective randomized controlled study
Abstract
OBJECTIVE
To evaluate the efficacy of Garcinia cambogia (hydroxy citric acid) alone or in combination with Silodosin on the clinical outcomes of lower urinary tract symptoms (LUTS/BPH).
METHODS
A prospective, randomized, controlled, double-blind study conducted on patients with LUTS/BPH. Eligible patients were assigned randomly to one of three groups. Group A (33 patients) received Silodosin, 8mg, once daily. Group B (35 patients) received Garcinia extract 500 mg TID. Group C (36 patients) received the combination of Silodosin, plus Garcinia extract. All participants were assessed for the changes in; the maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), Post-Void Residual (PVR), PV, and serum Prostatic Specific Antigen (PSA) levels, at the baseline and after 12 weeks of treatment.
RESULTS
The baseline data regarding Qmax, IPSS, PVR, PV & PSA showed non-significant differences between the three groups. After 12 weeks of treatment, all groups showed a significant improvement in both Qmax & IPSS (P> 0.001) and group C showed the best improvement. The PVR was significantly reduced in all groups (P > 0.001). The PV was significantly increased in group A (P = 0.006), whereas it was significantly reduced in groups B & C (P> 0.001). The PSA showed a non-significant increase in group A (P = 0.625), while it was significantly decreased in groups B & C (P > 0.001).
CONCLUSION
Treatment with Garcinia extract especially in combination with Silodosin may…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 36 participants or records.
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.